Tags

Type your tag names separated by a space and hit enter

Prospective, open-label, noncomparative study to assess cycle control, safety and acceptability of a new oral contraceptive containing gestodene 60 microg and ethinylestradiol 15 microg (Minesse).

Abstract

OBJECTIVE

A prospective, open-label, noncomparative, multicenter study was carried out in 163 women aged 18-39 (mean 25+/-5 years), who used an ultra-low-dose oral contraceptive pill (OCP) containing gestodene (GTD) 60 mug/ethinylestradiol (EE) 15 mug for 6 months. The objective of the study was to evaluate the acceptability, safety, bleeding patterns and premenstrual symptomatology in these women.

METHODS

Patients used the OCP from Days 1-24, followed by a 4-day pill-free interval from Days 25-28 of the menstrual cycle. Physical and gynecological examinations were carried out at baseline and after 3 and 6 months, at which time blood pressure, weight, hemoglobin, hematocrit, SGOT, SGPT and urinalysis were also assessed. The Moos Menstrual Distress Questionnaire (MDQ) was completed on three consecutive days (Days 25-27 of the cycle) at baseline and at the end of the third and sixth cycles. Patients kept a menstrual diary throughout the study.

RESULTS

A total of 146 women completed the study. Ten women discontinued because of adverse events and one undesired pregnancy occurred during treatment. No adverse metabolic effects were observed. The adverse event most frequently reported was breakthrough bleeding, which diminished, however, as the time of OC use increased. Cycle length and duration of bleeding decreased significantly with OC use (p<.01 and p<.05, respectively, after 6 months). Intensity of menstrual bleeding tended to decrease with OC use, but this difference was not statistically significant. Systolic and diastolic blood pressure were significantly lower after 6 months of OC use compared to baseline (p<.02). No alterations were recorded in body weight or laboratory evaluations. Statistically significant changes were found both in the total MDQ score and in several of the factors evaluated, and patients showed a statistically significant improvement in well-being with respect to premenstrual complaints and symptoms.

CONCLUSION

This OC regimen is safe, well-accepted and well-tolerated, affects menstrual patterns beneficially by reducing both the intensity and duration of bleeding, provides good cycle control and improves premenstrual symptomatology.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Maternidade Climério de Oliveira, Universidade Federal da Bahia, 40055-150 Salvador, Bahia, Brazil. barbosaic@terra.com.br

    , ,

    Source

    Contraception 73:1 2006 Jan pg 30-3

    MeSH

    Adolescent
    Adult
    Blood Pressure
    Contraceptives, Oral
    Ethinyl Estradiol
    Female
    Humans
    Menstrual Cycle
    Menstruation Disturbances
    Norpregnenes
    Pregnancy
    Prospective Studies
    Uterine Hemorrhage

    Pub Type(s)

    Journal Article
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    16371291

    Citation

    Barbosa, Ione C., et al. "Prospective, Open-label, Noncomparative Study to Assess Cycle Control, Safety and Acceptability of a New Oral Contraceptive Containing Gestodene 60 Microg and Ethinylestradiol 15 Microg (Minesse)." Contraception, vol. 73, no. 1, 2006, pp. 30-3.
    Barbosa IC, Filho CI, Faggion D, et al. Prospective, open-label, noncomparative study to assess cycle control, safety and acceptability of a new oral contraceptive containing gestodene 60 microg and ethinylestradiol 15 microg (Minesse). Contraception. 2006;73(1):30-3.
    Barbosa, I. C., Filho, C. I., Faggion, D., & Baracat, E. C. (2006). Prospective, open-label, noncomparative study to assess cycle control, safety and acceptability of a new oral contraceptive containing gestodene 60 microg and ethinylestradiol 15 microg (Minesse). Contraception, 73(1), pp. 30-3.
    Barbosa IC, et al. Prospective, Open-label, Noncomparative Study to Assess Cycle Control, Safety and Acceptability of a New Oral Contraceptive Containing Gestodene 60 Microg and Ethinylestradiol 15 Microg (Minesse). Contraception. 2006;73(1):30-3. PubMed PMID: 16371291.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Prospective, open-label, noncomparative study to assess cycle control, safety and acceptability of a new oral contraceptive containing gestodene 60 microg and ethinylestradiol 15 microg (Minesse). AU - Barbosa,Ione C, AU - Filho,Carlos Isaia, AU - Faggion,Dirceu,Jr AU - Baracat,Edmund Chada, Y1 - 2005/11/16/ PY - 2005/04/27/received PY - 2005/06/04/accepted PY - 2005/12/24/pubmed PY - 2006/5/5/medline PY - 2005/12/24/entrez SP - 30 EP - 3 JF - Contraception JO - Contraception VL - 73 IS - 1 N2 - OBJECTIVE: A prospective, open-label, noncomparative, multicenter study was carried out in 163 women aged 18-39 (mean 25+/-5 years), who used an ultra-low-dose oral contraceptive pill (OCP) containing gestodene (GTD) 60 mug/ethinylestradiol (EE) 15 mug for 6 months. The objective of the study was to evaluate the acceptability, safety, bleeding patterns and premenstrual symptomatology in these women. METHODS: Patients used the OCP from Days 1-24, followed by a 4-day pill-free interval from Days 25-28 of the menstrual cycle. Physical and gynecological examinations were carried out at baseline and after 3 and 6 months, at which time blood pressure, weight, hemoglobin, hematocrit, SGOT, SGPT and urinalysis were also assessed. The Moos Menstrual Distress Questionnaire (MDQ) was completed on three consecutive days (Days 25-27 of the cycle) at baseline and at the end of the third and sixth cycles. Patients kept a menstrual diary throughout the study. RESULTS: A total of 146 women completed the study. Ten women discontinued because of adverse events and one undesired pregnancy occurred during treatment. No adverse metabolic effects were observed. The adverse event most frequently reported was breakthrough bleeding, which diminished, however, as the time of OC use increased. Cycle length and duration of bleeding decreased significantly with OC use (p<.01 and p<.05, respectively, after 6 months). Intensity of menstrual bleeding tended to decrease with OC use, but this difference was not statistically significant. Systolic and diastolic blood pressure were significantly lower after 6 months of OC use compared to baseline (p<.02). No alterations were recorded in body weight or laboratory evaluations. Statistically significant changes were found both in the total MDQ score and in several of the factors evaluated, and patients showed a statistically significant improvement in well-being with respect to premenstrual complaints and symptoms. CONCLUSION: This OC regimen is safe, well-accepted and well-tolerated, affects menstrual patterns beneficially by reducing both the intensity and duration of bleeding, provides good cycle control and improves premenstrual symptomatology. SN - 0010-7824 UR - https://www.unboundmedicine.com/medline/citation/16371291/Prospective_open_label_noncomparative_study_to_assess_cycle_control_safety_and_acceptability_of_a_new_oral_contraceptive_containing_gestodene_60_microg_and_ethinylestradiol_15_microg__Minesse__ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0010-7824(05)00254-4 DB - PRIME DP - Unbound Medicine ER -